Medlab ramps up
ASX LISTED cannabis and nanodelivery system company Medlab has released progress results on its product development, including the successful completion of stage 1 of its Nanabis cancer trial at Sydney’s Royal North Shore Hospital.
Formal approval has been received from the Independent Data Safety Monitoring Board to proceed to Stage 2 of the trial, focusing again on safety alongside dosage escalation and tolerance.
Other developments include Medlab’s NanaBidialanti-emetic treatment which is about to commence a clinical trial for patients with chemotherapyinduced nausea, while a third announcement related to a trial of NanoStat, a nano-particle spray of a statin.
Called NanoCelle, the system enables delivery of small doses and with the trial now completed, results will be available in a month.
The company is also undertaking international negotiations to enhance global market penetration.